Estrada-Soto Samuel, Rendón-Vallejo Priscila, Villalobos-Molina Rafael, Millán-Pacheco César, Vázquez MiguelA, Hernández-Borja Fernando, Hernández-Núñez Emanuel
Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México.
Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, México.
Drug Res (Stuttg). 2022 Jan;72(1):53-60. doi: 10.1055/a-1616-0156. Epub 2021 Oct 18.
Several 4-pyran derivatives were designed and synthesized previously as vasorelaxant agents for potential antihypertensive drugs. In this context, the objective of the present investigation was to determine the functional mechanism of vasorelaxant action of 6-amino-3-methyl-4-(2-nitrophenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (1: ) and its antihypertensive effect. Thus, compound 1: showed significant vasorelaxant action on isolated aorta rat rings pre-contracted with serotonin or noradrenaline, and the effect was not endothelium-dependent. Compound 1: induced a significant relaxant effect when aortic rings were contracted with KCl (80 mM), indicating that the main mechanism of action is related to L-type calcium channel blockade. Last was corroborated since compound 1: induced a significant concentration-dependent lowering of contraction provoked by cumulative CaCl adding. Moreover, compound 1: was capable to block the contraction induced by FPL 64176, a specific L-type calcium channel agonist, in a concentration-dependent manner. On the other hand, docking studies revealed that compound 1: interacts on two possible sites of the L-type calcium channel and it had better affinity energy (-7.80+/-0.00 kcal/mol on the best poses) than nifedipine (-6.86+/-0.14 kcal/mol). Finally, compound 1: (50 mg/kg) showed significant antihypertensive activity, lowering the systolic and diastolic blood pressure on spontaneously hypertensive rats (SHR) without modifying heart rate.
先前设计并合成了几种4-吡喃衍生物作为潜在抗高血压药物的血管舒张剂。在此背景下,本研究的目的是确定6-氨基-3-甲基-4-(2-硝基苯基)-1,4-二氢吡喃并[2,3-c]吡唑-5-腈(化合物1)的血管舒张作用机制及其抗高血压作用。因此,化合物1对用血清素或去甲肾上腺素预收缩的离体大鼠主动脉环显示出显著的血管舒张作用,且该作用不依赖于内皮。当主动脉环用KCl(80 mM)收缩时,化合物1诱导出显著的舒张作用,表明其主要作用机制与L型钙通道阻滞有关。这一点得到了证实,因为化合物1通过累积添加CaCl₂诱导的收缩产生了显著的浓度依赖性降低。此外,化合物1能够以浓度依赖性方式阻断由特异性L型钙通道激动剂FPL 64176诱导的收缩。另一方面,对接研究表明化合物1在L型钙通道的两个可能位点相互作用,并且它比硝苯地平(-6.86±0.14 kcal/mol)具有更好的亲和能(在最佳构象上为-7.80±0.00 kcal/mol)。最后,化合物1(50 mg/kg)显示出显著的抗高血压活性,可降低自发性高血压大鼠(SHR)的收缩压和舒张压,而不改变心率。